Yasuhiro Miki

Dr. Yasuhiro Miki

Tohoku Universtiy
+1
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2012 in Cancer Science
Verified
Journal Article
Open access
PDF file
DIDaisuke Inoue
Daisuke Inoue
TSTakashi Suzuki
Takashi Suzuki
YMYoichiro Mitsuishi
Yoichiro Mitsuishi
YMYasuhiro Miki
Yasuhiro Miki
SSSatoshi Suzuki
Satoshi Suzuki
MYMasayuki Yamamoto
Masayuki Yamamoto
P62/SQSTM1 is a selective substrate of autophagy, and aberrant accumulation of p62 has been observed in various pathological conditions. To understand the roles p62 plays in non‐small‐cell lung cancer (NSCLC), we carried out immunohistochemical analyses of p62 expression in a cohort of patients with annotated clinicopathological data. As analyses of murine and human hepatocellular carcinomas suggested a correlation between p62 and Nrf2 accumulations, we also examined NRF2 expression in the same cohort. The expression of NRF2 and p62 was examined by immunohistochemical methods in 109 NSCLC cases, which included patients with adenocarcinoma (n = 72), squamous cell carcinoma (n = 31), and large cell carcinoma (n = 6). Accumulation of NRF2 and p62 was detected in 34% and 37% of NSCLC patients, respectively. The accumulations of p62 and NRF2 did not correlate with each other, but both were associated with worse lung cancer‐specific survival (P = 0.0003 for NRF2; P = 0.0130 for p62). NRF2 status had an impact on NSCLC prognosis irrespective of histology types, but p62 status did so particularly in adenocarcinoma (P = 0.037). Multivariate analysis indicated that positive immunoreactivities of NRF2 and p62 were both independent factors predicting worse lung cancer‐specific survival (P < 0.0001 for NRF2 and P = 0.04 for p62). This study revealed that both NRF2 and p62 are independent prognostic factors for NSCLC. The prognostic impact of p62 status was pronounced in adenocarcinoma patients, suggesting that molecular mechanisms underlying cancer evolution differ between adenocarcinoma and squamous cell carcinoma. (Cancer Sci 2012; 103: 760–766)

1 September 2012 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
YMYasuhiro Miki
Yasuhiro Miki
KOKatsuhiko Ono
Katsuhiko Ono
SHShuko Hata
Shuko Hata
TSTakashi Suzuki
Takashi Suzuki
HKHiroyuki Kumamoto
Hiroyuki Kumamoto
HSHironobu Sasano
Hironobu Sasano

1 December 2002 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
YMYasuhiro Miki
Yasuhiro Miki
TNTaisuke Nakata
Taisuke Nakata
TSTakashi Suzuki
Takashi Suzuki
ADAndrew David Darnel
Andrew David Darnel
TMTakuya Moriya
Takuya Moriya
HSHironobu Sasano
Hironobu Sasano
Estrogens play a key role in various target tissues. Enzymes involved in the biosynthesis and metabolism of these sex steroids also regulate estrogenic actions in these tissues. Estrone sulfate (E1S) is a major circulating plasma estrogen that is converted into the biologically active estrogen, estrone (E1), by steroid sulfatase (STS). E1 is also sulfated and reverted into E1S by estrogen sulfotransferase (EST). These two enzymes have recently been shown to play important roles in the in situ estrogen actions of various sex steroid-dependent human tumors. However, the distribution of STS and EST in normal adult and fetal human tissues remains largely unknown. Therefore, in this study, in addition to examining the tissue distribution of both STS and EST mRNA in human adult and fetal tissues using RT followed by quantitative PCR, we studied the activity of these enzymes using 3H-labeled E1/E1S as substrates in the homogenates of various human adult tissues. We also examined the localization of STS and EST protein in human adult and fetal tissues using immunohistochemistry, and that of EST mRNA in the adult kidney using laser dissection microscopy and PCR. STS mRNA, enzyme activity, and immunoreactivity were either absent or detected at very low levels in all adult and fetal tissues examined in this study. EST mRNA expression, however, was detected in all of the tissues examined, except for adult spleen and pancreas. EST enzyme activities were consistent with those of mRNA expression in the great majority of the tissues examined. Marked EST immunoreactivity was detected in hepatocytes, adrenal gland (adult, zona fasciculate to the reticularis; fetus, fetal zone), and epithelial cells of the gastrointestinal tract, smooth muscle cells of the tunica media in aorta, Leydig cells of the testis, and syncytiotrophoblast of the placenta. Patterns of EST immunolocalization were similar between adult and fetal human tissues, but EST immunoreactivity was detected in the urinary tubules of adult kidney, whereas in the fetal kidney, it was localized in the interstitial cells surrounding the urinary tubules. In the adult kidney, the presence of EST mRNA was also confirmed in the cells of urinary tubules using laser dissection microscopy and RT-PCR. Although the number of human tissues available for examination in this study was limited, our results suggest that between the enzymes involved in estrogen activation or inactivation, EST and not STS is the more widely expressed enzyme in various peripheral tissues in humans. We speculate that EST may play an important role in protecting peripheral tissues from possible excessive estrogenic effects.

1 February 2005 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
YMYasuhiro Miki
Yasuhiro Miki
TSTakashi Suzuki
Takashi Suzuki
CTChika Tazawa
Chika Tazawa
BBBruce Blumberg
Bruce Blumberg
HSHironobu Sasano
Hironobu Sasano

27 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CIChihiro Inoue
Chihiro Inoue
YMYasuhiro Miki
Yasuhiro Miki
RSRyoko Saito-Koyama
Ryoko Saito-Koyama
SHShuko Hata
Shuko Hata
JAJiro Abe
Jiro Abe
HSHironobu Sasano
Hironobu Sasano
Cancer-associated fibroblasts (CAFs) exert various effects upon biological behaviours of cancer. In this study, we examined the correlation of CAFs with the intra-tumoural immune system in the lung adenocarcinoma microenvironment. We studied 27 and 113 cases of lung adenocarcinoma tentatively as Cohorts 1 and 2, respectively. The patients in Cohort 1 received epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for recurrent lung adenocarcinoma. α-smooth muscle actin (α-SMA), a surrogate marker for CAFs, was examined by immunohistochemistry. We then examined the effects of CAFs isolated from lung cancer tissues on programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma cell lines. No significant associations were detected between α-SMA status and the ratios of CD8/CD4 and Foxp3/CD8 in Cohort 1. However, α-SMA status was significantly associated with PD-L1 status in both Cohorts 1 and 2. Conditioned medium of CAFs significantly induced PD-L1 expression in lung adenocarcinoma cell lines, A549, PC-9, and H1975. Among the cytokines examined by antibody array, C-X-C motif chemokine ligand 2 (CXCL2) increased PD-L1 mRNA expression in these cell lines. CXCL2 is therefore considered to have a potential to induce PD-L1 expression in lung adenocarcinoma cells as a result of an interaction between carcinoma cells and CAFs. These findings did firstly demonstrate that CAFs indirectly influenced tumour immunity through increasing PD-L1 expression in lung adenocarcinoma cells.

19 January 2006 in Cancer Letters
Verified
Journal Article
Closed access
YMYasuhiro Miki
Yasuhiro Miki
CCColin D. Clyne
Colin D. Clyne
TSTakashi Suzuki
Takashi Suzuki
TMTakuya Moriya
Takuya Moriya
RSRie Shibuya
Rie Shibuya
HSHironobu Sasano
Hironobu Sasano